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 Introduction 
 Psoriasis vulgaris is a common chronic inflammatory 
disease in both children and adults which leads to a severe 
burden concerning quality of life  [1, 2] . Recent studies 
have demonstrated two patient cohorts, one with early-
onset (type I) and the other with late-onset (type II) pso-
riasis  [3, 4] . In addition, psoriasis in childhood revealed a 
median age of onset between 7 and 10 years  [5–8] . Juvenile 
psoriasis differs from psoriasis beginning in adulthood 
and is characterised by an increased rate of guttate psoria-
sis following infections, particularly with streptococci, or 
psychosocial stress situations  [9] . Interestingly, only ap-
proximately 30–60% of children with juvenile psoriasis 
develop plaque-type psoriasis  [9] , predominantly affect-
ing the scalp, face and intertriginous areas. Like in adults, 
nail psoriasis is a common feature  [10] . Data from a Ger-
man statutory health insurance organization revealed a 
single-year prevalence of 0.71% in juvenile psoriasis  [11] . 
Further analysis of juvenile psoriasis showed a prevalence 
in the UK of about 0.6% in children 0–9 years old and of 
1.4% in children from 10 to 19 years  [12] .
 Atopic eczema represents a chronic inflammatory skin 
disorder with a burdensome disease pathology. It is char-
acterised by pathognomonic eczematous skin lesions, 
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 Abstract 
 Background: First studies have shown that juvenile psoria-
sis is associated with an increased prevalence of comorbid-
ity.  Objectives: We carried out a data analysis to character-
ise the profiles of comorbidity in children with psoriasis and 
atopic eczema.  Methods: Prevalence data were derived 
from the database of a German statutory health insurance 
company according to ICD-10 codes L40 (psoriasis) and L20 
(atopic eczema) of children up to 18 years insured in 2009. 
 Results: Data sets included 1.64 million persons and 
293,181 children. 1,313 children = 0.45% (0.42–0.47) had a 
diagnosis of psoriasis and 30,354 = 10.35% (10.24–10.47) 
had a diagnosis of atopic eczema. Obesity, hyperlipid-
aemia, arterial hypertension and diabetes were more often 
diagnosed in children with psoriasis in comparison to all 
children without psoriasis and to those with atopic eczema. 
 Conclusion: Children with psoriasis and atopic eczema 
show different and specific patterns of comorbidity which 
should be detected early and treated adequately. 
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typically with a flexural distribution, and often affects 
children’s faces. Atopic eczema is associated with psycho-
social stress and a family history of allergies  [13–15] . In 
general atopic eczema starts in early childhood and fea-
tures clinical symptoms including pruritus and skin dry-
ness. In children prevalence rates between 7.4 and 37% 
have been observed  [16] . In adults atopic eczema has been 
reported more rarely; in Germany the prevalence rate in 
a recent study was 1.3%  [17] .
 Comorbidity is an important feature both of psoriasis 
and atopic eczema in adults  [18–21] . In contrast, epide-
miologic data on children are rare. In a previous study it 
was shown that patients with juvenile psoriasis also show 
increased rates of cardiovascular disease and metabolic 
syndrome  [11] , whereas children with atopic eczema show 
a strong association with other atopic diseases, especially 
allergic rhinitis and bronchial asthma  [22, 23] . However, 
in these analyses it was unclear whether there is a report-
ing bias due to more frequent physician visits among those 
patients. In order to control for such bias and to obtain 
further insight in the pattern of comorbidity, the study 
reported below was performed. Moreover our study pro-
vides the first comparative data of prevalence and comor-
bidity both in psoriasis and in atopic eczema.
 Methods 
 Prevalence data were derived from the database of a German 
statutory health insurance company (Gmünder Ersatzkasse) ac-
cording to ICD-10 codes L40 (PSO) for psoriasis and L20 (AE) for 
atopic eczema. Data extraction involved all data sets of persons 
younger than 18 insured in 2009. In addition, prevalence rates of 
comorbidity were evaluated by ICD-10 diagnoses. These includ-
ed among others allergic rhinitis, arterial hypertension, arthritis, 
bronchial asthma, diabetes mellitus, hyperlipidaemia, ischaemic 
heart disease, obesity, metabolic syndrome, ulcerative colitis and 
vitiligo.
 Statistics 
 Descriptive data analyses were conducted and calculated with 
the statistical program SAS by the Centre for Social Policy Re-
search, University of Bremen, Bremen, Germany. For comorbidi-
ty, prevalence ratios were performed by comparing the prevalence 
rate of children in the psoriatic and atopic eczema group to the 
respective rate in the non-psoriatic and non-atopic eczema groups. 
Prevalences are given as percentage values. For comparison of co-
morbidities, prevalence ratios were calculated by relating the prev-
alence rate of children in the psoriatic group and the atopic der-
matitis group with the respective rate in the non-psoriatic and 
non-atopic dermatitis group. Their corresponding 95% confi-
dence intervals were computed by a general method based on con-
stant χ 2 boundaries. Differences with a probability of a type I (α) 
error of  ≤ 0.05 were considered statistically significant.
 Results 
 The data set comprised 1.64 million persons nation-
wide, including 293,181 children and young adults up to 
18 years (150,244 boys, 142,937 girls). 1,313 children = 
0.45% (0.42–0.47) carried the diagnosis of psoriasis and 
30,354 = 10.35% (10.24–10.47) that of atopic eczema 
( fig.  1 ). The data demonstrate that the psoriasis preva-
lence in children correlates in a linear manner with age, 
whereas the prevalence of atopic eczema shows an early 
peak in the ages between 1 and 6 years and a consecutive 
lower rate. The prevalence of juvenile psoriasis increased 
from 0.13% (0.10–0.18) at the age of 0–2 years to 0.67% 
(0.62–0.73) at the age of 14–18 years. In contrast, the 
prevalence of children with atopic eczema decreased 
from 17.13% (16.65–17.62) at the age of 0–2 years to 7.3% 























 Fig. 1. Prevalence of psoriasis ( a ) and atopic eczema ( b ) in children 
according to age groups. 
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 The most frequent comorbidity in psoriasis was al-
lergic rhinitis (15.16%), bronchial asthma (12.19%) and 
obesity (7.08%) ( table 1 ). In addition obesity, hyperlip-
idaemia, arterial hypertension and diabetes were more 
often diagnosed in patients with psoriasis compared to 
the control groups of children without psoriasis and pa-
tients with atopic eczema, respectively. Thus the preva-
lence rate of obesity was significantly elevated among 
young patients with psoriasis (7.08%) compared to chil-
dren without psoriasis (3.61%) and patients with atopic 
eczema (4.11%). The prevalence rates of hyperlipid-
aemia (1.14%), arterial hypertension (0.91%) and diabe-
tes mellitus (0.61%) were elevated in comparison to all 
children without psoriasis (0.64%, 0.44%, 0.31%) and to 
those with atopic dermatitis (0.71%, 0.40%, 0.34%). Fur-
thermore high relative risks were found especially in 
psoriasis for arthritis and iridocyclitis. Thus arthritis 
and iridocyclitis were seen 15.3 and 9.6 times as often in 
psoriatic patients as in children without psoriasis, re-
spectively ( table 1 ).
 In atopic eczema the most frequent comorbidity ob-
served was allergic rhinitis (19.64%), followed by bron-
chial asthma (19.04%) ( table 1 ). High relative risks were 
found in atopic eczema for impetigo and vitiligo. Thus 
impetigo and vitiligo were seen 3.4 and 3.3 times as often 
in patients with atopic eczema as in children without this 
atopic disease. Furthermore bronchial asthma and aller-
gic rhinitis were seen 3.1 and 3.0 times as often in atopic 
dermatitis patients as in children without this disease, re-
spectively.
 Although both diseases, psoriasis and atopic eczema, 
may share some allergic disorders, we observed signifi-
cant differences between patients with psoriasis or atopic 
eczema and children without these diseases regarding the 
prevalence of comorbidities ( table 1 ).
 Table 1.  Prevalence (%) and prevalence ratios of selected comorbidities in children with psoriasis (n = 1,313) and without psoriasis 









PR 95% CI p
Arthritis 0.15 0.01 15.25 3.64 – 63.98 + 0.01 0.01 2.00 0.57 – 6.97 –
Iridocyclitis 0.38 0.04 9.55 3.90 – 23.42 + 0.06 0.03 2.00 1.20 – 3.33 +
Alopecia areata 0.46 0.12 3.82 1.70 – 8.58 + 0.21 0.09 2.34 1.77 – 3.08 +
Nail disorders 2.89 0.93 3.17 2.29 – 4.39 + 1.29 0.78 1.66 1.49 – 1.85 +
Ulcerative colitis 0.15 0.05 3.05 0.75 – 12.32 – 0.07 0.04 1.75 1.10 – 2.79 +
Atopic eczema 24.52 10.29 2.83 2.50 – 3.21 + 100.00 0.00 n.a. n.a. n.a.
Impetigo 3.35 1.47 2.32 1.72 – 3.14 + 3.57 1.07 3.42 3.19 – 3.68 +
Contact dermatitis 3.66 1.73 2.16 1.61 – 2.88 + 3.61 1.32 2.80 2.61 – 3.00 +
Arterial hypertension 0.91 0.44 2.09 1.18 – 3.69 + 0.40 0.39 1.03 0.85 – 1.24 –
Vitiligo 0.23 0.11 2.08 0.67 – 6.49 – 0.26 0.08 3.26 2.51 – 4.22 +
Diabetes mellitus 0.61 0.31 1.97 0.98 – 3.96 – 0.34 0.26 1.31 1.06 – 1.61 +
Obesity 7.08 3.61 1.89 1.53 – 2.34 + 4.11 3.10 1.34 1.26 – 1.42 +
Hyperlipidaemia 1.14 0.64 1.79 1.08 – 2.99 + 0.71 0.55 1.29 1.12 – 1.49 +
Viral warts 12.11 7.29 1.75 1.48 – 2.07 + 9.76 6.10 1.66 1.60 – 1.73 +
Depression 1.29 0.77 1.69 1.05 – 2.73 + 0.83 0.67 1.24 1.09 – 1.42 +
Keratitis 0.53 0.32 1.67 0.79 – 3.52 – 0.33 0.28 1.18 0.96 – 1.45 –
Allergic rhinitis 15.16 9.70 1.66 1.43 – 1.93 + 19.64 7.44 3.04 2.95 – 3.14 +
Bronchial asthma 12.19 9.36 1.34 1.14 – 1.59 + 19.04 7.16 3.05 2.95 – 3.15 +
Herpes infection 2.74 2.12 1.30 0.93 – 1.81 – 3.41 1.71 2.03 1.89 – 2.17 +
Ischaemic heart disease 0.08 0.06 1.27 0.18 – 9.07 – 0.08 0.05 1.60 1.04 – 2.47 +
ADHD 8.07 7.14 1.14 0.94 – 1.39 – 8.11 6.10 1.36 1.30 – 1.42 +
Urticaria 2.28 2.03 1.13 0.79 – 1.62 – 3.61 1.60 2.30 2.15 – 2.46 +
Chronic bronchitis 2.21 2.10 1.05 0.73 – 1.52 – 3.88 1.64 2.42 2.27 – 2.59 +
Crohn’s disease 0.00 0.07 0.00 n.a. n.a. 0.08 0.06 1.33 0.87 – 2.04 –
 ADHD = Attention deficit hyperactivity disorder; AE = atopic eczema; CI = confidence interval; n.a. = not applicable; PR = preva-








 This data analysis was conducted in order to obtain 
further insight into the prevalence and the comorbidity 
patterns of patients with juvenile psoriasis and atopic ec-
zema. The data set of patients from the German statutory 
health insurance Gmünder Ersatzkasse has been shown 
to be robust and valid for epidemiologic research  [24] . 
The prevalence data in children between 0 and 18 years 
of 0.45% for psoriasis and 10.35% for atopic eczema are 
within the same range as published in earlier studies. The 
results confirm previous data on the dimension of pso-
riasis prevalence in childhood and adolescence  [11] . Al-
though there is a difference in prevalence of 0.7% as pre-
viously described  [11] versus 0.45% in this study, the di-
mension of psoriasis in children remains significant. Our 
prevalence data confirm results of a study in the UK  [12] . 
In that study, within the first 10 years the prevalence of 
psoriasis in the UK was 0.55% and thus similar to our data 
(0.45%). Also the prevalence in juvenile psoriasis increas-
es constantly from early childhood up to the age of 18 
years ( fig.  1 ), whereas the prevalence in children with 
atopic dermatitis decreases over the years, underlining 
fundamental differences between these two common dis-
orders.
 The present study was conducted in order to further 
analyse comorbidities in patients with psoriasis and 
atopic dermatitis. It is remarkable that there are specific 
comorbidity patterns in this large data set from the 
health insurance companies, which confirms clinical 
findings from other epidemiologic studies in children 
with psoriasis and atopic eczema  [11, 20] . Specifically, 
clusters of comorbidities that are known to be associated 
with adult psoriasis  [25–32] are also seen in juvenile 
psoriasis. In contrast to atopic dermatitis, children with 
psoriasis are characterised by a significantly elevated 
prevalence of obesity, hyperlipidaemia, arterial hyper-
tension, diabetes and other forms of the metabolic syn-
drome.
 In light of these observations, it has been reported that 
patients with psoriasis may show signs of insulin resis-
tance and are at risk of developing metabolic disorders, 
hypothetically labelled the ‘psoriatic march’  [19] . The 
present data indicate that metabolic disorders may al-
ready occur in juvenile psoriasis, and screening and inter-
disciplinary management are advised.
 Atopic eczema in children is of high prevalence and 
characterised by concomitant atopic diseases, in partic-
ular allergic rhinitis and bronchial asthma. Interesting-
ly, when compared to healthy children, these comorbid-
ities are noted to be mildly but significantly elevated also 
in psoriasis. There seems to be a subgroup of children 
who – within the limitations of health insurance data – are 
even affected by both psoriasis and atopic eczema (24.5% 
of children with psoriasis also are affected by atopic ec-
zema). Furthermore, impetigo and vitiligo were seen 3.4 
and 3.3 times as often in children with atopic eczema. It 
is well known that disorders such as impetigo contagio-
sa and vitiligo are more often associated with atopic der-
matitis  [4, 20] . Our results give support to these find-
ings.
 The coding of medical entities with the ICD-10 clas-
sification in Germany is used for reimbursement, and 
the reliability and disease severity of diagnosis coding is 
still not clear  [33] . However, with regard to the evalua-
tion of population-based studies in Germany, ICD-10 
coding often is the only available information. Thus lim-
itations in the study, which appear in the analysis of 
health insurance data, cannot be completely ruled out. 
This includes the option of incorrect diagnoses, since 
these were not verified by the authors. Moreover the 
prevalence rates can only be attributed to those patients 
seeking medical care. It may be possible that children 
with psoriasis and atopic eczema fail to seek medical 
care. However, this rate probably is low, since there is a 
high burden of disease to the children and their families 
in both disorders and there is no financial burden from 
physician visits to the children and their families in Ger-
many  [11, 20] . Moreover, studies on psoriasis care and 
self-medication in Germany by pharmacies have shown 
that very few patients buying medication and doing self-
medication in Germany do not refer to a prescription. 
Furthermore most Germans are insured, since health 
care provision is based on a statutory health insurance 
system  [34] . Until now, only few validation studies for 
routine data of German statutory health insurances ex-
ist, and the true underlying number of children with 
each ICD-10 diagnosis can only be estimated. However, 
a current study focused on the validity of the coded di-
agnosis of the used data set with regard to the coding of 
general practitioners in Berlin  [35] . In that trial the au-
thors reported a correctness of musculoskeletal disorder 
coding of 61% and of M54 coding for dorsalgia of 71% 
 [35] .
 Our data confirm known differences in the comorbid-
ity spectrum seen in psoriasis and atopic eczema in adults. 
As shown here, children with psoriasis show increased 
comorbidity associated with obesity. In contrast, atopic 
eczema in children is associated with significantly in-
creased rates of atopic comorbidity such as allergic rhini-
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tis and bronchial asthma. These specific patterns and the 
differences between children with psoriasis and with 
atopic eczema indicate that there is no overreporting bias 
in this study due to just an increased rate of physician vis-
its. In total, it can be assumed that the basic outcomes of 
the study both on the disease prevalence and the preva-
lence of comorbidity are valid for the German popula-
tion. The data support the importance of the German na-
tional health care goals, which demand early detection 
and treatment of psoriasis and its comorbidity in chil-
dren. The same claim must also be set for children with 
atopic eczema.
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